?Product Name?: Edoxaban Impurity 29
?CAS No.?: 852291-42-0

?? ?Product Overview?
Edoxaban Impurity 29 is a high-purity reference standard essential for quality control in the synthesis of ?Edoxaban? (CAS 480449-70-5), a widely used ?direct oral anticoagulant (DOAC)?. This impurity plays a critical role in pharmaceutical R&D and regulatory compliance, ensuring the safety and efficacy of Edoxaban API batches. With ?≥98% purity? (HPLC-certified), it is ideal for analytical testing and impurity profiling. Available in flexible quantities (1g–100g) to meet lab and industrial needs.

?? ?Key Advantages?
? ?Ultra-High Purity?: ≥98% (HPLC/GC-tested), ensuring reliable results in API quality control.
?? ?Scalable Supply?: Custom packaging options (1g, 5g, 100g) for research and production.
?? ?Regulatory Compliance?: Meets pharmacopeial standards for impurity analysis in anticoagulant development.

?? ?Applications?

1. ?API Manufacturing?: Critical for impurity identification and control in Edoxaban production.

2. ?Pharmaceutical R&D?: Supports synthesis of generic anticoagulants post-patent expiration.

3. ?Quality Assurance?: Used in global pharmaceutical QC laboratories to validate batch consistency.

?? ?Quality Certification?

• ?Testing Methods?: HPLC, GC, NMR, and mass spectrometry.

• ?Standards Compliance?: Aligns with ISO 9001 and ICH guidelines for pharmaceutical intermediates.

?? ?Market Trends?
The demand for Edoxaban impurities is surging due to ?patent expirations (2024–2026)? and the rapid growth of generic DOAC markets. The global anticoagulant sector is projected to expand at ?7.9% CAGR (2025–2030)?, with Asia-Pacific leading API production. Suppliers offering ?GMP-ready impurities? are prioritized for cost-effective generic drug manufacturing.